Pokrzyk Justyna, Kulczyńska-Przybik Agnieszka, Guzik-Makaruk Ewa, Winkel Izabela, Mroczko Barbara
Department of Neurodegeneration Diagnostics, Medical University of Białystok, 15-269 Bialystok, Poland.
Faculty of Law, University of Bialystok, 15-213 Białystok, Poland.
Int J Mol Sci. 2025 Feb 24;26(5):1935. doi: 10.3390/ijms26051935.
The role of amyloid beta peptide (Aβ) in memory regulation has been a subject of substantial interest and debate in neuroscience, because of both physiological and clinical issues. Understanding the dual nature of Aβ in memory regulation is crucial for developing effective treatments for Alzheimer's disease (AD). Moreover, accurate detection and quantification methods of Aβ isoforms have been tested for diagnostic purposes and therapeutic interventions. This review provides insight into the current knowledge about the methods of amyloid beta detection in vivo and in vitro by fluid tests and brain imaging methods (PET), which allow for preclinical recognition of the disease. Currently, the priority in the development of new therapies for Alzheimer's disease has been given to potential changes in the progression of the disease. In light of increasing amounts of data, this review was focused on the diagnostic and therapeutic employment of amyloid beta in Alzheimer's disease.
由于生理和临床方面的问题，β淀粉样蛋白（Aβ）在记忆调节中的作用一直是神经科学领域备受关注和争议的话题。了解Aβ在记忆调节中的双重性质对于开发治疗阿尔茨海默病（AD）的有效疗法至关重要。此外，已对Aβ异构体的准确检测和定量方法进行了测试，用于诊断目的和治疗干预。本综述深入探讨了目前通过液体检测和脑成像方法（PET）在体内和体外检测淀粉样β的方法的相关知识，这些方法能够实现疾病的临床前识别。目前，阿尔茨海默病新疗法开发的重点在于疾病进展的潜在变化。鉴于数据量的不断增加，本综述聚焦于淀粉样β在阿尔茨海默病诊断和治疗中的应用。
